Achieve Life Sciences, Inc. (ACHV)

Market Cap	151.27M
Revenue (ttm)	n/a
Net Income (ttm)	-50.42M
Shares Out	51.10M
EPS (ttm)	-1.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	519,150
Open	3.070
Previous Close	3.080
Day's Range	2.960 - 3.090
52-Week Range	1.840 - 5.310
Beta	1.54
Analysts	Strong Buy
Price Target	16.00 (+440.54%)
Earnings Date	Nov 6, 2025

About ACHV

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Richard A. Stewart
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: ACHV
• Website: https://www.achievelifesciences.com

Analyst Summary

According to 2 analysts, the average rating for ACHV stock is "Strong Buy." The 12-month stock price target is $16.0, which is an increase of 440.54% from the latest price.

Price Target

$16.0

(440.54% upside)

Analyst Consensus: Strong Buy